Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

BackgroundLMB-100 is a mesothelin (MSLN)-targeting recombinant immunotoxin (iTox) carrying a Pseudomonas exotoxin A payload that has shown promise against solid tumors, however, efficacy is limited by the development of neutralizing anti-drug antibodies (ADAs). Tofacitinib is an oral Janus Kinase (J...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Nebojsa Skorupan, Cody J. Peer, Xianyu Zhang, Hyoyoung Choo-Wosoba, Mehwish I. Ahmad, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Yunkai Yu, Guillaume Joe Pegna, Seth M. Steinberg, Shelley S. Kalsi, Liang Cao, William D. Figg, Jane B. Trepel, Ira Pastan, David FitzGerald, Christine Alewine
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-04-01
coleção:	Frontiers in Oncology
Assuntos:	JAK inhibition immunotoxin anti-drug antibodies pericarditis mesothelin
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1386190/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!